Clinical Trial Update: First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating first-line carboplatin and paclitaxel with pembrolizumab, followed by maintenance pembrolizumab with or without nesuparib, in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Nesuparib (nesuparib)
• PACLITAXEL (PACLITAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Yonsei University | Conditions: Endometrial Cancer, Recurrent Endometrial Carcinoma | Phase 2 | Status: RECRUITING